Aller au contenu principal
Profil bibliographique

Tsofia Inbar

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

18Publications signalées
250Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Lymphoma Diagnosis and TreatmentCAR-T cell therapy researchChronic Lymphocytic Leukemia ResearchCancer Immunotherapy and BiomarkersCNS Lymphoma Diagnosis and Treatment

Les publications récentes

2026 article OpenAlex

Platelet and Fibrinogen Dynamics After CAR ‐T Cell Therapy in Relapsed/Refractory B‐Cell Lymphoma May Predict ICANS Onset

Hazim Khatib, Amit Parizat, Jabour Halloun, Roni Shouval et autres

ABSTRACT CAR‐T cell therapy is efficient in relapsed/refractory B‐cell lymphoma; yet, cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) remain major and potentially life‐threatening complications, which makes their prediction and prevention crucial. This international, retrospective study analyzed the predictive …

il, us (code pays fourni par la source)

0 citations European Journal Of Haematology
2024 article OpenAlex

Eosinophilic pleocytosis in the cerebrospinal fluid following CAR-T cell therapy for CNS lymphoma: A case for warning?

Mayasa Abu Ata, Israel Henig, Dana Yehudai‐Ofir, Inna Tzoran et autres

INTRODUCTION: Chimeric antigen receptor T (CAR-T) cell therapy, emerging as an efficient treatment option for patients with secondary central nervous system (CNS) lymphoma, is frequently complicated with immune effector cell-associated neurotoxicity syndrome (ICANS). CASE PRESENTATION: We report a case of a 64-year-old …

il (code pays fourni par la source)

0 citations Acta Haematologica
Accès ouvert 2024 article OpenAlex

Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely B‐cell depleted patients with persistent COVID ‐19

Tsofia Inbar, Eldad J. Dann, Omer Kerner, Anat Stern

BACKGROUND: Patients with severe B-cell depletion related to hematological malignancies or B-cell targeted therapy suffer from impaired antibody responses to SARS-CoV-2 and are at risk for prolonged COVID-19. In this population, COVID-19 convalescent plasma (CCP) may provide passive immunity, enhance immune response, …

il (code pays fourni par la source)

4 citations Transfusion
2023 conference-abstract OpenAlex

A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax (GIVeRS) in Patients with Richter's Syndrome

Tamar Tadmor, Ohad Benjamini, Neta Goldschmidt, Natalia Kreiniz et autres

Background: Richter's syndrome (RS) is an aggressive histologic transformation of chronic lymphocytic leukemia (CLL), most commonly to diffuse large B-cell lymphoma (DLBCL). RS is characterized by a rapid clinical course, low responses to therapy, and poor long-term survival. Chemoimmunothreapy for RS achieves …

il (code pays fourni par la source)

4 citations Blood
Accès ouvert 2023 article OpenAlex

P1076: PREVALENCE OF SOMATIC GENETIC MUTATIONS IN HRS CELLS OF HODGKIN LYMPHOMA PATIENTS FROM EASTERN MEDITERRANEAN, ASSESSED WITH, CIRCULATING TUMOR DNA, DIFFERS FROM THAT FOUND IN EUROPEAN COHORTS

Eldad J. Dann, Jamela Eisa, Tsofia Inbar, Shada Sarji et autres

Topic: 17. Hodgkin lymphoma - Clinical Background: The incidence of Hodgkin lymphoma (HL) among the Eastern Mediterranean population is very high. The highest rates are reported in Lebanese males (4.2x105) followed by Israeli males (3.7x105), with values being similar in Jews and …

il (code pays fourni par la source)

1 citation HemaSphere
2022 article OpenAlex

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Shimrit Harlev, Nashwa Fadaos, Tehila Azoulay, Ronit Leiba et autres

The results of the PRIMA trial published a decade ago, substantiated the benefit of maintenance therapy with anti-CD20 monoclonal antibodies (MoAb), following chemo-immunotherapeutic induction, for prolongation of the progression-free survival (PFS) of patients with high-tumor- burden follicular lymphoma (FL). Rituximab-associated delayed neutropenia, …

il (code pays fourni par la source)

0 citations Blood
Accès ouvert 2022 article OpenAlex

P1078: PATIENTS WITH HODGKIN LYMPHOMA DEVELOP ADEQUATE HUMORAL SEROLOGICAL RESPONSE TO VACCINATION WITH TWO DOSES OF BNT162B2 AND THEIR IGG ANTIBODY LEVELS MARKEDLY INCREASE AFTER A THIRD VACCINE DOSE

Eldad J. Dann, Tsofia Inbar, Tania Mashiach, Jamela Eisa et autres

Background: In patients (pts) with hematological malignancies, COVID-19 is considered to be associated with a high risk of severe morbidity and mortality. While anti-COVID-19 vaccination of such pts has become the standard of care, pts undergoing lymphodepleting therapy fail to generate protective …

il (code pays fourni par la source)

0 citations HemaSphere
Accès ouvert 2022 article OpenAlex

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS

Ronit Gurion, Uri Rozovski, Gilad Itchaki, A. Gafter-Gvili et autres

Background: In most individuals, protective humoral and cellular immunity develops after two doses of the BNT162b2 Pfizer vaccine. In patients with lymphoma, humoral response is weaker and almost universally abrogated in patients who received anti-CD20 monoclonal antibodies. Whether cellular immune response is …

il (code pays fourni par la source)

0 citations HemaSphere
Accès ouvert 2021 conference-abstract OpenAlex

Patients with Hodgkin Lymphoma Develop Adequate Humoral Serological Response to Vaccination with Two Doses of BNT162b2

Eldad J. Dann, Tsofia Inbar, Tania Mashiach, Jamela Eisa et autres

Abstract Introduction: In patients with hematological malignancies, COVID-19 is considered to be associated with a high risk of severe morbidity and mortality. While anti-COVID-19 vaccination of such patients has become the standard of care, many of them fail to generate protective serological …

il (code pays fourni par la source)

0 citations Blood
Accès ouvert 2021 article OpenAlex

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Ronit Gurion, Uri Rozovski, Gilad Itchaki, Anat Gafter‐Gvili et autres

Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies, suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine …

il (code pays fourni par la source)

60 citations Haematologica
Accès ouvert 2021 article OpenAlex

Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy

Liza Barki‐Harrington, Orna Baron‐Epel, Adir Shaulov, Luiza Akria et autres

BACKGROUND: One of the main obstacles of providing home-based palliative care to transfusion-dependent hematology patients is the lack of home transfusions services. While healthcare professionals are concerned with safety and cost of home transfusions, the attitude of the patients toward home transfusions …

il (code pays fourni par la source)

14 citations Palliative Medicine
2019 article OpenAlex

Low risk for viral reactivation during induction for acute myeloid leukemia in patients with resolved hepatitis B infection

Tsofia Inbar, Shehrban Sobeh Khalil, Ron Ram, Chezi Ganzel et autres

The natural history of chronic hepatitis B virus (HBV) infection is highly dependent on the immune response of the infected individual. Patients on immunosuppressive therapy, with prior exposure to...

il (code pays fourni par la source)

0 citations Leukemia & lymphoma/Leukemia and lymphoma

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.